Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (January 2019)
24 slides from Artelo Biosciences's investor presentation, January 2019
Slide 1: A clinical stage biopharmaceutical company targeting the endocannabinoid system
A clinical stage biopharmaceutical company developing and commercializing a portfolio of novel therapeutic candidates targeting the endocannabinoid system OTCQB: ARTL January 2019
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this Artelo Biosciences presentation that are not historical facts are "forward-looking statements" subject to risks/uncertainties. Such statements are based on current facts/analyses and other information that are based on forecasts of results, estimates of
Slide 3: Company Highlights
Company Highlights NOVEL DRUG ROBUST NEAR-TERM HIGH-GROWTH PROVEN PIPELINE PATENT ESTATE MILESTONES SECTOR LEADERSHIP TEAM Portfolio approach Comprehensive Upcoming IP, pre- Cannabis-based Experienced team of to endocannabinoid issued and pending clinical milestones Pharmaceutical pharmaceutical sys
Slide 4: Using Endocannabinoid System (ECS) Modulation to Improve Health
Using Endocannabinoid System (ECS) Modulation to Improve Health The ECS is a family of receptors and neurotransmitters that form a biochemical communication network throughout the body ▪ Involved in regulating a variety of physiological and cognitive processes ▪ May be applicable to multiple disease
Slide 5: Three Primary Approaches to Modulating the ECS
Three Primary Approaches to Modulating the ECS Modulating the ECS can be accomplished through several treatment strategies ▪ Naturally occurring cannabinoids are chemical compounds that exist Naturally in nature Occurring Cannabinoids ▪ Synthetic cannabinoids are small molecules with cannabinoid-lik
Slide 6: Artelo's Portfolio Approach to Modulating the ECS
Artelo’s Portfolio Approach to Modulating the ECS Artelo is developing a portfolio of product candidates designed to modulate the ECS with the potential of best-in-class compounds in each therapeutic strategy COMPANY METHODOLOGY Artelo Biosciences Naturally Occurring GW Pharmaceuticals Cannabinoids
Slide 7: Development Pipeline
Development Pipeline Product Pre-clinical Phase 1 Phase 2 Highlights Candidate Target Markets: Anorexia / Cachexia • Anorexia: 60% of cancer patients ART 27.13 • Lung cancer: $6.2B Dual CB1/CB2 Patent Estate: Agonist Anti-Cancer • Multiple issued patents (US & Intl) including composition of matter T
Slide 8: ART 27.13 Cancer / Anorexia Clinical Program
ART 27.13 CANCER / ANOREXIA CLINICAL PROGRAM
Slide 9: ART27.13 – Cannabinoid Agonist that Targets the Body not the Brain
ART27.13 – Cannabinoid Agonist that Targets the Body not the Brain ART 27.13 • Peripherally restricted, highly-potent, synthetic agonist that enables systemic metabolic effects Monkey PET Scan with [11C]-ART27.13 Brain: Plasma Ratio = 0.5 while minimizing CNS mediated toxicity CANCER / ANOREXIA CLIN
Slide 10: ART27.13 – Exposure & Weight Gain Correlation Observed in a Phase 1 Study
ART27.13 – Exposure & Weight Gain Correlation Observed in a Phase 1 Study ART 27.13 (125-250 μg) Multiple ascending dose (MAD) clinical study results over 12 days CANCER / ANOREXIA CLINICAL PROGRAM • 25% of subjects gained 3% or greater of baseline body weight • Acceptable side effect profile at Obs
Slide 11: ART 12.11 Proprietary Cocrystal CBD Program
ART 12.11 PROPRIETARY COCRYSTAL CBD PROGRAM
Slide 12: CBD's Protection Challenge for Pharmaceutical Development
CBD’s Protection Challenge for Pharmaceutical Development ARTART Opportunity Challenge 12.11 A product containing CBD as the sole active ingredient was CBD is in the public domain 12.11 PROPRIETARY FDA approved in June 2018 PROPRIETARY Market exclusivity strategies COCRYSTAL Rare disease Cocrystaliz
Slide 13: CBD's Inherent Polymorphism Challenge for Drug Development
CBD’s Inherent Polymorphism Challenge for Drug Development ART 12.11 ▪ Polymorphism in pharmaceuticals refers to the The molecular structure of the two independent molecules ability of a solid material to exist in two or more of cannabidiol (CBD), with the atom labelling, indicating inherent polymor
Slide 14: ART12.11 Cannabidiol (CBD) Cocrystal: The Same and Different
ART12.11 Cannabidiol (CBD) Cocrystal: The Same and Different ART 12.11 The Same - US FDA perspective: Cocrystals can be Different - US Patent Office perspective: engineered to enhance bioavailability, stability and Cocrystals can be new and distinct solid state improve chemical processing. Essential
Slide 15: ART 26.12 FABP5 Inhibitor
ART 26.12 a Artelo FABP5 INHIBITOR BIOSCIENCES
Slide 16: ART26.12 – Endocannabinoid Modulator Development Led to Cancer Discovery
ART26.12 – Endocannabinoid Modulator Development Led to Cancer Discovery ART 26.12 • FABP5 is an intra-cellular protein that serves as a carrier for certain lipids, including endocannabinoids and fatty acids • ART26.12 is a small molecule FABP5 inhibitor FABP5 INHIBITOR developed at Stony Brook Univ
Slide 17: FABP5 is Upregulated in Breast, Prostate, and Cervical Cancer
FABP5 is Upregulated in Breast, Prostate, and Cervical Cancer ART 26.12 In cancer patients, FABP5 is upregulated, correlates with tumor grade, and is associated with poor prognosis Genetic silencing of FABP5 is anti-tumor FABP5 INHIBITOR ART 26.12 FAB5 INHIBITOR Data above from breast cancer. Liu et
Slide 18: FABP5 Inhibitor Decreases Tumor Growth in Prostate Cancer Model
FABP5 Inhibitor Decreases Tumor Growth in Prostate Cancer Model ART 26.12 FABP5 INHIBITOR ART 26.12 FAB5 INHIBITOR SBFI26 = ART26.12 Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5 W. Al-Jameel, Oncotarget, 2017, V
Slide 19: Company
COMPANY ' then Artelo
Slide 20: Use of Funds and Upcoming Milestones
Use of Funds and Upcoming Milestones 2018 2019 2020 ART 27.13 CANCER CELL LINE EXERCISE FULL Dual CB1 / SCREENING RESULTS LICENSE OPTION CB2 Agonist PHASE 2 STUDY ANOREXIA ASSOCIATED WITH CANCER ART 12.11 PRE-IND FDA Proprietary FILE IND CLINICAL STUDY MEETING Cannabidiol (CBD) COMPOSITION OF MATTER
Slide 21: Building Shareholder Value
Building Shareholder Value Creating Value with Potential 2 Commercialized (THC/CBD & CBD) GW Pharmaceuticals (GWPH) 1 Phase 3 Best-in-Class Therapeutics $4.6B 2 Phase 2 1 Commercialized Our novel programs, patent 1 Phase 3 $658M Insys Therapeutics (INSY) portfolio, and proven team are the 2 Phase 2
Slide 22: Company Capitalization
Company Capitalization As of January 18, 2019 Exchange: Symbol OTCQB: ARTL Ownership Summary 46% Market Cap USD $17.5M Shares Outstanding 15,282,687 Warrants 5,242,687 34% Options 400,000 20% Fully Diluted 20,925,374 Officers, Directors, Employees Founder Shareholders OUR COMPANY Series A warrant st
Slide 23: Proven Leadership
Proven Leadership EXECUTIVE MANAGEMENT BOARD OF DIRECTORS SCIENTIFIC COLLABORATORS GREGORY GORGAS CONNIE MATSUI SAOIRSE O’SULLIVAN, PhD Chair of the Board University of Nottingham, UK, President & CEO, Director Nominating & Governance Committee Chair Cannabinoid Research Expert Biogen Idec, Chiron,
Slide 24: For more information: www.artelobio.com
For more information: www.artelobio.com
Artelo Biosciences — Investor Presentation (January 2019) on 6ix